Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Biovail, Former CEO Melnyk Settle Proxy Fight

By Pharmaceutical Processing | May 26, 2009

NEW YORK (AP) — Biovail Corp. and its former Chief Executive have settled their ongoing proxy fight ahead of the biotechnology company’s annual meeting. Founder and former CEO Eugene Melnyk, along with EM Holdings which he controls, had been urging shareholders to vote for two board nominees. The company urged shareholders not to vote for those nominees. Under the settlement, Melnyk agreed to vote his and EM Holdings’ roughly 16.4 million shares — representing roughly a 10 percent stake — in favor of the company’s nominees, while withdrawing one of his own nominees. Biovail, meanwhile, will appoint one of Melnyk’s nominees, Frank Potter, to the board immediately following the meeting. Melnyk has also agreed to refrain from participating in any proxy contest or shareholder proposal until the completion of Biovail’s shareholders’ meeting in 2010. Biovail and Melnyk have been in a years’ long dispute over the direction of the company that started with his retirement in 2007. Melnyk, the owner of the Ottawa Senators National Hockey League team, retired after he and Biovail were accused of accounting fraud. He remains a major shareholder and wants the company to continue focusing on generic drugs while current management wants to concentrate on treatments for central nervous system disorders. In 2008, he attempted to change the company’s leadership by proposing his own 10 candidates for the board of directors. Earlier in 2009, the company settled investigations with U.S. and Canadian authorities alleging that it defrauded and deceived investors from 2001 to March 2004. The company’s annual meeting is scheduled for Thursday in Toronto.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE